Antimicrobial TSifran. Drug ojiji

Medicine "TSifran" bụ antimicrobial gị n'ụlọnga na a iche iche sara mbara nke edinam na bụ nke pharmacological ìgwè nke fluoroquinolones. Ifịk ifịk mmiri nke ọgwụ bụ ciprofloxacin na tinidazole. N'ihi suppression nke DNA gyrase na nje DNA njikọ mgbochi, ndị a-arụ ọrụ bekee nwere ihe dị ukwuu n'ọrụ n'ihi na ọtụtụ gram-adịghị mma microorganisms.

Karịsịa, ọrụ nke bactericidal edinam nke nkwadebe "TSifran" ntụziaka ntuziaka ndetu na-akwanyere ndị a bacteria: Neisseriagonorrhoeae, Neisseriameningitidis, Haemophilusinfluenzae, Pseudomonasaeruginosa, Salmonellaspp, Escherichiacoli na ndị ọzọ microorganisms pụta amị na-adịghị amị penicillinase, nakwa dị ka methicillin-eguzogide ọgwụ na Enterococcusspp, Chlamydiaspp, Mycobacteriumspp, Legionellaspp ... pụta.

Pharmacological edinam nke bactericidal agwọ ọrịa iche iche sara mbara "TSifran" ntuziaka maka ojiji bụ dị ka ndị a: "Na ngwá ọrụ na-zubere maka ọgwụgwọ nke na-efe efe pathologies irè na ọgwụgwọ nke mkpali Filiks - mbuaha na-efe efe iwe na ọrụ nke aerobic na anaerobic microorganisms na mmadụ nje.".

Pharmacokinetics

The n'ọrụ Efrata nke ọgwụ "TSifran" ntuziaka maka ojiji na-ezo aka ukwuu dakọtara. Na ciprofloxacin na tinidazole nwere ezi absorption na eriri afọ tract.

Ịtụle ọ bụla nke nọ n'ọrụ Efrata nke ọgwụ, ọ ga-ahụ kwuru ciprofloxacin nwere banyere 70% bioavailability. Ya absorption na-slowed dịtụ, mgbe ojiji nke a nri. A ọgwụ nwere ezigbo permeability n'ime anụ ahụ na mmiri ahụ, gụnyere ọkpụkpụ, uru ahụ, abụba, na cartilage anụ ahụ. Ọ penetrates n'ime akụkụ nke urinary usoro, gụnyere na a ahụ dị ka prostate. Ọ bụ a na nzuzo ọ na-ekpughe a akwa ịta content kiprofloksatsina, dị ka, n'ezie, na semen, asu, bile, Lymph ọmụmụ, imi.

Tinidazole dị iche iche zuru bioavailability. Nke a akụrụngwa na-dara ngwa ngwa na elu kasịnụ ke anụ ahụ nke ahụ mmadụ na mmiri mmiri na-ajụ penetrates, akpan akpan ke cerebrospinal ọmụmụ, nke a na-lekwasị ke otu dị ka plasma larịị. About a nkeji iri na ise nke ego nke ingested bekee anyụpụ na mmamịrị na-agbanweghi agbanwe, banyere 10% a tọhapụrụ n'ụdị metabolites, nnọọ obere akụkụ nke akụrụngwa doo ahụ na faeces.

Egosi maka ọgwụ "TSifran" ntuziaka maka ojiji na-ezo aka mbuaha ọgwụgwọ nke na-efe efe Filiks. Otu ihe kpọmkwem pathologies, maka ọgwụgwọ nke ọgwụ n'okpuru echiche nke na-eji, ndị na-esonụ ọrịa:

• adịghị ala ala osteomyelitis ;

• intra-efe efe mkpali Filiks;

• amoebic ọnyụnyụ ọbara na ọnyụnyụ ọbara na mbuaha ụdị (amoebic na nje);

• periodontitis, periostitis na ndị ọzọ na-efe efe nke na-edeghị ede oghere;

• gynecological mkpali daa ọrịa;

• adịghị ala ala Sinusitis;

• na-efe efe nke akpụkpọ adụ anụ ahụ;

• postoperative nje ọrịa;

• akpa ume etuto.

Otu n'ime ha, na ndị ọzọ na-efe efe mere site aerobic na anaerobic bacteria chebaara ihe nke ọgwụ mmiri.

Nabatara nkwadebe "TSifran" postprandial. Mbadamba kwesịrị iwere na mmiri zuru ezu quantities. Okenye ọrịa na-ewere ọgwụ ugboro abụọ n'ụbọchị nke a mbadamba nkume nke 500 / 600mg ma ọ bụ abụọ 250 / 300mg. Ọrịa n'okpuru afọ iri na asatọ afọ, ọgwụ na-adịghị ndinọ. Ọ na-adịghị na-atụ aro maka ojiji na ime.

Contraindications na ojiji nke kọwara ọgwụ na ọgwụ bụ ubara uche na mmiri na-akpụ akụkụ nke tsifran na daa ọrịa ọbara, porphyria.